[go: up one dir, main page]

MXPA02012896A - Combinaciones de estatinas, agentes estrogenicos y opcionalmente estrogenos. - Google Patents

Combinaciones de estatinas, agentes estrogenicos y opcionalmente estrogenos.

Info

Publication number
MXPA02012896A
MXPA02012896A MXPA02012896A MXPA02012896A MXPA02012896A MX PA02012896 A MXPA02012896 A MX PA02012896A MX PA02012896 A MXPA02012896 A MX PA02012896A MX PA02012896 A MXPA02012896 A MX PA02012896A MX PA02012896 A MXPA02012896 A MX PA02012896A
Authority
MX
Mexico
Prior art keywords
statins
combinations
estrogenic agents
estrogens
optionally
Prior art date
Application number
MXPA02012896A
Other languages
English (en)
Inventor
Christopher Paul Miller
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of MXPA02012896A publication Critical patent/MXPA02012896A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
MXPA02012896A 2000-07-06 2001-06-29 Combinaciones de estatinas, agentes estrogenicos y opcionalmente estrogenos. MXPA02012896A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21609600P 2000-07-06 2000-07-06
US21618400P 2000-07-06 2000-07-06
PCT/US2001/021085 WO2002003977A2 (en) 2000-07-06 2001-06-29 Combinations of statins, estrogenic agents and optionally estrogens

Publications (1)

Publication Number Publication Date
MXPA02012896A true MXPA02012896A (es) 2003-10-24

Family

ID=26910656

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02012896A MXPA02012896A (es) 2000-07-06 2001-06-29 Combinaciones de estatinas, agentes estrogenicos y opcionalmente estrogenos.

Country Status (8)

Country Link
EP (1) EP1359940A2 (es)
JP (1) JP2004502731A (es)
CN (1) CN1468110A (es)
AU (1) AU2001271785A1 (es)
BR (1) BR0112365A (es)
CA (1) CA2414060A1 (es)
MX (1) MXPA02012896A (es)
WO (1) WO2002003977A2 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006504409A (ja) 2002-07-24 2006-02-09 チルドレンズ ホスピタル メディカル センター 鏡像異性のエクオールを含有する組成物および製品、およびその製造方法
US8668914B2 (en) 2002-07-24 2014-03-11 Brigham Young University Use of equol for treating skin diseases
AU2003286781B2 (en) 2002-10-29 2009-05-21 Brigham Young University Use of equol for treating androgen mediated diseases
US8580846B2 (en) 2002-10-29 2013-11-12 Brigham Young University Use of equol for ameliorating or preventing neuropsychiatric and neurodegenerative diseases or disorders
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
BR112018006121B1 (pt) 2015-10-01 2024-01-23 Olema Pharmaceuticals, Inc COMPOSTOS DE TETRA-HIDRO-1H-PIRIDO[3,4-b]INDOL, COMPOSIÇÕES COMPREENDENDO OS REFERIDOS COMPOSTOS E USOS DOS MESMOS
HRP20221462T1 (hr) 2015-12-09 2023-01-20 The Board Of Trustees Of The University Of Illinois Selektivni nishodni regulatori receptora estrogena na bazi benzotiofena
EP3455218A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
CN109562113A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的螺环降解决定子体
CN109562107A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的杂环降解决定子体
EP3455219A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. AMINE-RELATED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
MX2019000200A (es) 2016-07-01 2019-09-26 G1 Therapeutics Inc Agentes antiproliferativos basados en pirimidina.
WO2018081168A2 (en) 2016-10-24 2018-05-03 The Board Of Trustees Of The University Of Illinois Benzothiophene-based selective mixed estrogen receptor downregulators
EP3565558B1 (en) 2017-01-06 2023-12-06 G1 Therapeutics, Inc. Combination therapy with a serd compound and a cdk4/6 inhibitor for the treatment of cancer
TW201835064A (zh) 2017-02-10 2018-10-01 美商G1治療公司 苯并噻吩雌激素受體調節劑
CN110769822A (zh) 2017-06-20 2020-02-07 C4医药公司 用于蛋白降解的n/o-连接的降解决定子和降解决定子体
EP3645001B1 (en) 2017-06-29 2024-07-03 G1 Therapeutics, Inc. Morphic forms of git38 and methods of manufacture thereof
EP3897631A4 (en) 2018-12-20 2022-11-23 C4 Therapeutics, Inc. TARGETED PROTEIN DEGRADATION
WO2021007146A1 (en) 2019-07-07 2021-01-14 Olema Pharmaceuticals, Inc. Regimens of estrogen receptor antagonists
PE20221724A1 (es) 2019-12-20 2022-11-04 C4 Therapeutics Inc Compuestos de isoindolinona e indazol para la degradacion del receptor del factor de crecimiento epidermico (egfr)
KR20220166797A (ko) 2020-03-05 2022-12-19 씨4 테라퓨틱스, 인코포레이티드 Brd9의 표적화된 분해를 위한 화합물
IL300397A (en) 2020-08-05 2023-04-01 C4 Therapeutics Inc Compounds for targeted knockdown of RET
EP4565585A1 (en) 2022-08-03 2025-06-11 Bristol-Myers Squibb Company Compounds for modulating ret protein
KR20250116017A (ko) 2022-11-04 2025-07-31 브리스톨-마이어스 스큅 컴퍼니 Ret-ldd 단백질 억제제
WO2024097989A1 (en) 2022-11-04 2024-05-10 Bristol-Myers Squibb Company Ret-ldd protein degraders
WO2025006753A2 (en) 2023-06-30 2025-01-02 Merck Patent Gmbh Heterobifunctional compounds for the degradation of kras protein

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3894299A (en) * 1998-05-15 1999-12-06 American Home Products Corporation Compositions comprising 2-phenyl-indole compounds and estrogen formulations
GEP20033079B (en) * 1998-05-15 2003-10-27 Wyeth Corp Pharmaceutical Compositions for Treatment of Diseases Caused by Estrogens Deficiency

Also Published As

Publication number Publication date
WO2002003977A3 (en) 2003-09-04
BR0112365A (pt) 2003-05-13
CN1468110A (zh) 2004-01-14
AU2001271785A1 (en) 2002-01-21
JP2004502731A (ja) 2004-01-29
WO2002003977A2 (en) 2002-01-17
CA2414060A1 (en) 2002-01-17
EP1359940A2 (en) 2003-11-12

Similar Documents

Publication Publication Date Title
MXPA02012896A (es) Combinaciones de estatinas, agentes estrogenicos y opcionalmente estrogenos.
MXPA02012897A (es) Combinaciones de bisfosfonatos, agentes estrigenicos y opcionalmente estrogenos.
AU5208401A (en) 3-nitrogen-6,7-dioxygen steroids and uses related thereto
MXPA02012891A (es) Composiciones farmaceuticas de agentes estrogenicos.
MXPA03000499A (es) Sistema y metodo de electrocardiografia inalambrica.
ZA200203316B (en) New use and novel n-azabicyclo-amide derivatives.
MXPA03005445A (es) Barra colectora 12c para aislar los circuitos integrados seleccionados para una comunicacion rapida de barra colectora 12c.
ZA200204165B (en) Fulvestrant formulation.
MXPA03002410A (es) 4-amino-quinazolinas.
MXPA03001983A (es) Exemestano como agente quimiopreventivo.
ZA200207489B (en) Apomorphine derivatives and methods for their use.
EG23373A (en) Process and intermediates.
MXPA03003522A (es) Panal.
EG23262A (en) Delta -pyrrolines.
ZA200302014B (en) Methods and compositions for promoting the maturation of monocytes.
MXPA03001591A (es) Derivados y analogos de 10-aril-11-h-benzo(b) fluorena para uso medicinal.
MXPA03001877A (es) 2-guanidin-4-arilquinazolinas.
IL144455A0 (en) 16-hydroxyestratrienes as selective estrogens
MXPA03002668A (es) Guanidinas de sulfonilo.
MXPA03005714A (es) Sulfamidotienopirimidinas.
MXPA03002411A (es) 4-amino-quinazolinas.
AU2001238027A1 (en) Cellular coupon system
MXPA03005494A (es) Benzoilpiridazinas.
MXPA03002521A (es) Triazol-epotilona.
MXPA01000464A (es) Composicion.